Advertisement

Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial

Published:September 16, 2020DOI:https://doi.org/10.1016/j.diabres.2020.108451

      Abstract

      Aims

      To explore associations between multimorbidity condition counts (total; concordant (diabetes-related); discordant (unrelated to diabetes)) and glycaemia (HbA1c; glycaemic variability (GV); time in range (TIR)) using data from a randomised controlled trial examining effectiveness of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D).

      Methods

      Cross-sectional study: 279 people with T2D using baseline data from the General Practice Optimising Structured MOnitoring To Improve Clinical outcomes (GP-OSMOTIC) trial from 25 general practices in Australia. Number of long-term conditions (LTCs) in addition to T2D used to quantify total/concordant/discordant multimorbidity counts. GV (measured by coefficient of variation (CV)) and TIR derived from CGM data. Multivariable linear regression models used to examine associations between multimorbidity counts, HbA1c (%), GV and TIR.

      Results

      Mean (SD) age of participants 60.4 (9.9) years; 40.9% female. Multimorbidity was present in 89.2% of participants. Most prevalent comorbid LTCs: hypertension (57.4%), painful conditions (29.8%), coronary heart disease (22.6%) and depression (19.0%). No evidence of associations between multimorbidity counts, HbA1c, GV and TIR.

      Conclusions

      While multimorbidity was common in this T2D cohort, it was not associated with HbA1c, CV or TIR. Future studies should explore factors other than glycaemia that contribute to the increased mortality observed in those with multimorbidity and T2D.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Barnett K.
        • Mercer S.W.
        • Norbury M.
        • Watt G.
        • Wyke S.
        • Guthrie B.
        Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study.
        Lancet. 2012; 380: 37-43
        • Smith S.M.
        • Ferede A.
        • O'Dowd T.
        Multimorbidity in younger deprived patients: an exploratory study of research and service implications in general practice.
        BMC Family Pract. 2008; 9: 6
      1. Australian Bureau of Statistics. National Health Survey: First Result, 2014-15; 2015.

        • Chiang J.I.
        • Hanlon P.
        • Li T.C.
        • Jani B.D.
        • Manski-Nankervis J.A.
        • Furler J.
        • et al.
        Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts.
        PLoS Med. 2020; 17e1003094
        • Mair F.S.
        • May C.R.
        Thinking about the burden of treatment.
        BMJ. 2014; 349g6680
        • Harris M.F.
        • Dennis S.
        • Pillay M.
        Multimorbidity: Negotiating priorities and making progress.
        AFP. 2013; 42: 850-854
        • Piette J.D.
        • Kerr E.A.
        The impact of comorbid chronic conditions on diabetes care.
        Diab Care. 2006; 29: 725-731
      2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.

        • Cox D.
        • Gonder-Frederick L.
        • McCall A.
        • Kovatchev B.
        • Clarke W.
        The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes.
        Int J Clin Pract Suppl. 2002; 129: 20-26
      3. Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics. Diab Care 2018;41(6):e92.

        • Danne T.
        • Nimri R.
        • Battelino T.
        • Bergenstal R.M.
        • Close K.L.
        • DeVries J.H.
        • et al.
        International Consensus on Use of Continuous Glucose Monitoring.
        Diab Care. 2017; 40: 1631-1640
        • Battelino T.
        • Danne T.
        • Bergenstal R.M.
        • Amiel S.A.
        • Beck R.
        • Biester T.
        • et al.
        Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
        Diab Care. 2019; (dci190028)
        • Monnier L.
        • Mas E.
        • Ginet C.
        • Michel F.
        • Villon L.
        • Cristol J.P.
        • et al.
        Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
        JAMA. 2006; 295: 1681-1687
        • Nalysnyk L.
        • Hernandez-Medina M.
        • Krishnarajah G.
        Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature.
        Diab Obes Metab. 2010; 12: 288-298
        • Beck R.W.
        • Bergenstal R.M.
        • Riddlesworth T.D.
        • Kollman C.
        • Li Z.
        • Brown A.S.
        • et al.
        Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
        Diab Care. 2019; 42: 400
        • Guo Q.
        • Zang P.
        • Xu S.
        • Song W.
        • Zhang Z.
        • Liu C.
        • et al.
        Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese Type 2 Diabetes.
        J Diab Res. 2020; 2020: 5817074
        • Lu J.
        • Ma X.
        • Zhou J.
        • Zhang L.
        • Mo Y.
        • Ying L.
        • et al.
        Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes.
        Diab Care. 2018; 41: 2370-2376
        • Chiang J.I.
        • Jani B.D.
        • Mair F.S.
        • Nicholl B.I.
        • Furler J.
        • O'Neal D.
        • et al.
        Associations between multimorbidity, all-cause mortality and glycaemia in people with type 2 diabetes: A systematic review.
        PLoS ONE. 2018; 13e0209585
        • Chiang J.I.
        • Furler J.
        • Mair F.S.
        • Jani B.
        • Nicholl B.I.
        • Jenkins A.
        • et al.
        Impact of multimorbidity count on all-cause mortality and glycaemic outcomes in people with type 2 diabetes: a systematic review protocol.
        BMJ Open. 2018; 8
        • Jani B.D.
        • Hanlon P.
        • Nicholl B.I.
        • McQueenie R.
        • Gallacher K.I.
        • Lee D.
        • et al.
        Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort.
        BMC Med. 2019; 17: 74
        • Furler J.
        • O'Neal D.
        • Speight J.
        • Blackberry I.
        • Manski-Nankervis J.A.
        • Thuraisingam S.
        • et al.
        Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
        Lancet Diab Endocrinol. 2020; 8: 17-26
        • Furler J.
        • O'Neal D.N.
        • Speight J.
        • Blackberry I.
        • Manski-Nankervis J.A.
        • Thuraisingam S.
        • et al.
        GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice.
        BMJ Open. 2018; 8e021435
        • Thuraisingam S.
        • Chondros P.
        • Catchpool M.
        • Dalziel K.
        • Manski-Nankervis J.A.
        • Speight J.
        • et al.
        Update on the General Practice Optimising Structured Monitoring to Improve Clinical Outcomes in Type 2 Diabetes (GP-OSMOTIC) trial: statistical analysis plan for a multi-centre randomised controlled trial.
        Trials. 2019; 20: 93
        • Cheung N.W.
        • Conn J.J.
        • d'Emden M.C.
        • Gunton J.E.
        • Jenkins A.J.
        • Ross G.P.
        • et al.
        Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus.
        Med J Aust. 2009; 191: 339-344
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • Payne J.
        • Gonzalez N.
        • Conde J.G.
        Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inform. 2009; 42: 377-381
        • Hill N.R.
        • Oliver N.S.
        • Choudhary P.
        • Levy J.C.
        • Hindmarsh P.
        • Matthews D.R.
        Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.
        Diab Technol Ther. 2011; 13: 921-928
      4. Freestyle Libre Flash Glucose Monitoring System User's Manual [Available from: https://freestyleserver.com/Payloads/IFU/2017_oct/ART28697-409_rev-A_Web.pdf.

      5. Australian Bureau of Statistics (ABS). Census of population and housing: Socio-economic indexes for areas (SEIFA), Australia; 2011: Australian Bureau of Statistics; 2013 [Available from: http://www.abs.gov.au/ausstats/[email protected]/DetailsPage/2033.0.55.0012011?OpenDocument.

        • Luijks H.
        • Schermer T.
        • Bor H.
        • van Weel C.
        • Lagro-Janssen T.
        • Biermans M.
        • et al.
        Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study.
        BMC Med. 2012; 10: 128
        • Higashi T.
        • Wenger N.S.
        • Adams J.L.
        • Fung C.
        • Roland M.
        • McGlynn E.A.
        • et al.
        Relationship between number of medical conditions and quality of care.
        New Engl J Med. 2007; 356: 2496-2504
        • Xu F.
        • Zhao L.-h.
        • Su J.-b.
        • Chen T.
        • Wang X-q.
        • Chen J.-f.
        • et al.
        The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c.
        Diabetol Metabolic Syndrome. 2014; 6: 139
        • Tang X.
        • Li S.
        • Wang Y.
        • Wang M.
        • Yin Q.
        • Mu P.
        • et al.
        Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c.
        Clin Chim Acta. 2016; 461: 146-150